NRx Pharmaceuticals

Company Overview

Snapshot

Founded in October 2014 by Daniel C. Javitt and Jonathan C. Javitt, NRx Pharmaceuticals operates with 11–50 employees. The company has raised a total of $176.18 million across seven funding rounds. In May 2021, NRx Pharmaceuticals went public on NASDAQ.

Business overview

NRx Pharmaceuticals is a specialized biopharmaceutical company focused on addressing high unmet medical needs for central nervous system (CNS) diseases, specifically severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company's pipeline leverages a proprietary, dual-targeted mechanism of action that modulates NMDA and 5HT2A receptors. NRx Pharmaceuticals operates within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals, and aims to deliver breakthrough science to patients with life-threatening conditions.

Strategic signal

In September 2025, NRx Pharmaceuticals' subsidiary HOPE Therapeutics completed the acquisition of Dura Medical, marking an initial step in building a network of interventional psychiatry clinics. This strategic acquisition signals the company's expansion beyond drug development into direct patient care infrastructure, indicating a move towards integrated solutions for mental health treatment and potentially accelerating market access for its therapies.

Company Intelligence Q&A

What was a significant recent development for NRx Pharmaceuticals' subsidiary, HOPE Therapeutics?

In September 2025, NRx Pharmaceuticals' subsidiary HOPE Therapeutics, Inc. completed the acquisition of Dura Medical, which represents an initial acquisition in a network of interventional psychiatry clinics.

What regulatory milestone did NRx Pharmaceuticals achieve for its IV Ketamine formulation?

In September 2025, NRx Pharmaceuticals secured FDA Fast Track designation for its IV Ketamine formulation NRX-100 for suicidal depression.

What was the outcome of NRx Pharmaceuticals' suitability petition for preservative-free ketamine?

In September 2025, NRx Pharmaceuticals received notification of US Food and Drug Administration approval of a suitability petition for its proposed strength of preservative-free ketamine.

What was NRx Pharmaceuticals' activity regarding its Abbreviated New Drug Application (ANDA) for KETAFREE™?

In September 2025, NRx Pharmaceuticals re-filed its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV Ketamine.

What was a key development for NRx Pharmaceuticals regarding its NRX-100 product in September 2024?

In September 2024, NRx Pharmaceuticals announced the completion of twelve months of stability testing on the first manufactured commercial scale lot of NRX-100 (Ketamine).